Vivani™ is an innovative,
clinical stage biopharmaceutical company.
Leveraging our proprietary NanoPortal™ platform technology, we are developing a portfolio of miniature, drug implants to address two main barriers of optimal chronic disease treatment: poor medication adherence and tolerability. Our lead asset, NPM-139, is a miniature, six-month, GLP-1 (semaglutide) implant under development for chronic weight management/obesity.
We seek to maximize the benefit and minimize the burden of treatment for patients with chronic conditions.
We believe our growing portfolio could help patients live free from the administration hassles of daily or weekly medications. For physicians, caregivers and loved ones, this would mean greater confidence that patients are receiving their prescribed doses and potentially achieving better clinical outcomes.
Developing drug implants with the potential to guarantee medication adherence and improve tolerability.
NPM-139 is a semaglutide implant candidate under investigation for chronic weight management in obese or overweight individuals.
NPM-133 is a semaglutide implant candidate under investigation for type 2 diabetes.
Positioning Vivani for
pipeline execution.
We strive to build the future of Vivani through both a strong capital base and the expertise of our entrepreneurial innovators. Our scientists and executives pool their collective knowledge in drug development, implant technology and chronic diseases to drive our pipeline forward.
Building a revolutionary machine-to-human interface.
Cortigent is a subsidiary of Vivani developing targeted neurostimulation systems to help patients recover critical body functions and regain control of their lives. Their technology combines innovative neuroscience with proprietary microelectronics, software, and data processing capabilities to provide artificial vision and potentially restore muscle movement during stroke rehabilitation.
Cortigent is advancing the pioneering work of legacy company, Second Sight Medical Products, whose revolutionary product, the Argus II® Retinal Prosthesis System, is the world’s first and only device authorized by the FDA to provide artificial vision to people with profound blindness.
In July 2026, Vivani announced that we had entered into a definitive agreement and plan of merger of Cortigent and ClearOne, Inc., a publicly traded company (Nasdaq: CLRO). Completion of the Cortigent-ClearOne merger and initiation of trading of the new company Cortigent Holdings (d/b/a Cortigent) on the Nasdaq exchange under the ticker symbol CRGT is anticipated in the third quarter of 2026. For more information, email info@cortigent.com.